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Bovine milk exosomes (BMEs) have attracted attention as vehicles for delivering RNA 
therapeutics. BMEs originate in mammary alveolar cells. Here, we determined whether bovine 
mammary alveolar MAC-T cells are a promising tool to assess RNA delivery by BMEs. MAC-T 
cells exosomes (MAC-T BMEs) and BMEs were harvested by differential ultracentrifugation. 
Exosome size, morphology, microRNA content and marker proteins were assessed using 
nanoparticle tracking analysis, transmission electron microscopy, real-time PCR and immunoblot 
analysis, respectively. MAC-T cells were genetically engineered to secrete MAC-T BMEs 
endogenously labeled with a near-infrared fluorescent protein and tissue distribution was 
compared to fluorophore-labeled BMEs following intravenous injection in C57BL/6 mice. 
Morphology and size were similar in MAC-T BMEs and BMEs (94 ± 5.8 nm and 101 ± 4.2 nm, 
p > 0.05). Both preparations expressed miR-320a, miR-200c and let-7a-5p (positive controls) but 
not miR-1 (negative control). Exosome marker proteins, CD9, CD63, CD81 and Tsg101, were 
detected in both MAC-T BMEs and BMEs. The distribution in mouse tissues was similar for 
both preparations, with liver being the primary accumulation site. Collectively, MAC-T BMEs 
are a promising tool for BMEs-based RNA delivery studies.  
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Limitations of conventional cancer therapy 
Although advanced understanding of cancer biology has led to the development of improved 
cancer therapeutics, cancer remains one of the leading causes of death worldwide due to 
unfavorable pharmacokinetics of therapeutics [1] [2]. 
Chemotherapy is the most common type of cancer therapy, and it employs free anticancer drugs 
and, more recently, RNA therapeutics (such as siRNA) to inhibit cancer progression [3]. siRNA 
is of particular importance because of their ability to stop tumor progression at the molecular 
level by knocking down key genes that govern cell proliferation, angiogenesis, metastasis and 
apoptosis [4]. However, the therapeutic index of free anticancer drugs and unmodified RNA 
therapeutics is suboptimal due to their non-specificity for tumor cells, rapid systemic clearance 
by the reticuloendothelial cells, unstable physicochemical properties, off target effects, rapid 
clearance by the reticuloendothelial cells, reduced therapeutic concentrations in target cells, and 
uniform distribution to both diseased and normal cells resulting in dose-limiting toxicity [5] [6] 
[7]. Hence, a protective and targeted delivery system is needed to improve their therapeutic 
effects [1]. 
Nanoparticles- mediated drug delivery 
The application of nanoparticle mediated drug delivery significantly enhanced the therapeutic 
potential of therapeutics by increasing their systemic stability allowing for their increased 
accumulation at the target site [8]. Typically, nanoparticles are small sized (20 nm-500 nm) 
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particles that possess interior core for drug packaging and an exterior core that can be decorated 
with functional peptides [9]. The small size of nanoparticles enables them to evade systemic 
clearance while their interior core confers stability and protection on encapsulated drugs and 
nucleic acids [10]. Synthetic lipid nanoparticles such as liposomes and polymeric micelles were 
the first to be explored in nanoparticle-based therapy and have been approved for clinical use 
[11]. Synthetic nanoparticles have substantially improved the efficacy of anticancer agents and 
therapeutics by increasing their therapeutic concentrations at the target site and reducing the off-
target side effects [6]. However, they are fraught with issues such as inefficient cargo delivery, 
formation of aggregates, induction of immune response, systemic toxicity, and poor stability 
[12]. In contrast, exosomes have natural ability to protect and deliver functional biomolecules to 
target cells with low immunogenicity [13]. Hence, they have recently gained traction in the 
pharmaceutical industry as potential drug packaging and delivery systems [14-16].  
Exosomes are natural extracellular nanoparticles (30-150 nm) secreted by virtually all cell types 
for cell-to-cell communication. [17]. Their formation is highly coordinated: first, the endosomal 
membrane invaginates to form intraluminal vesicles (ILVs) enclosed within large multivesicular 
bodies (MVBs); these MVBs then either fuse with the plasma membrane to release ILVs into the 
extracellular space as exosomes or are mobilized for lysosomal degradation [18, 19]. Before their 
release into the extracellular space, labile cargos such as miRNAs, lipids and proteins are 
selectively incorporated into exosomes [20] (Fig 1.). Intracellular communication is achieved 
through the interaction of exosomes with the surface of recipient cells or the delivery of regulatory 
cargos (miRNAs) to recipient cells [21, 22]. Exosomes have an advantage over synthetic 
3 
 
nanoparticles in targeted drug delivery because they are more natural, stable, bioavailable and less 
toxic compared to synthetic nanoparticles. [23, 24].  
A       B  
Figure 1. 1 Formation of exosomes and their secretion into the extracellular. Exosomes’ uptake 
and cargo release in recipient cells space (A). Their release into the extracellular space (B). 
Adapted from Raposo et al., 2013 [25]. 
Exosomes from different sources such as milk, plasma and cell cultures have been explored for 
clinical translatability [24] (Fig. 2). This is necessary because exosomes possess a repertoire of 
cell-specific lipids and protein markers on their surface that determine their biological functions 
and tissue distribution pattern in-vivo [26]. For instance, tumor cell derived exosomes contain 
tumor associated biomolecules that induce metastatic behavior in normal cells [27]. Also, 
exosomes secreted by dendritic cells carry antigens that stimulate immune responses [28]. It is 
therefore crucial to carefully assess the biological properties and functions of exosomes and their 






Figure 1. 2 Exosomes sources and their advantages. Bovine milk exosomes have superior drug 
delivery properties than exosomes secreted by cancer cells and dendritic cells. Illustration 
created with BioRender.com 
Bovine milk exosomes for drug delivery 
Bovine milk exosomes (BMEs) are extensively explored as promising vehicles for the delivery of 
RNA therapeutics due to their high yield, safety, cost effectiveness and natural ability to deliver 
functional biomolecules to target cells [29, 30]. BMEs are generally considered safe for drug 
delivery because of the prominent role of bovine milk in human nutrition [31]. Moreover, previous 
studies have reported that BMEs do not elicit significant immunogenic effect in humans and rats 
[32]. Bovine milk is cheap, readily accessible in most geographical regions and is a scalable source 
of exosomes [33]. Our lab has previously demonstrated that BMEs and their miRNA cargos are 
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absorbed and transported by endocytosis in human endothelial cells [34]. Baier et al. were the first 
to report a postprandial increase in plasma concentration of milk miRNA following milk 
consumption [21]. Also, Manca et al. revealed that synthetic miRNAs encapsulated within BMEs 
could be delivered  to the liver, intestinal tract, brain, and spleen in mice [35]. Mature miRNAs 
are non-coding RNAs (~22 nucleotides in length) that can degrade mRNAs or inhibit their 
translation depending on their complementarity [36-38]. Approximately 60 % of human genes are 
regulated by miRNAs [39]. BMEs can overcome placenta barrier [40]. Sadri et al., reported that 
BMEs-mediated delivery of synthetic miRNAs (miR-21-5p and miR-30d) elicited gene expression 
changes in murine placenta and increased fetal implantation [41]. It was recently reported that 
encapsulation of siRNA into BMEs facilitated their intracellular delivery and gene silencing 
activity in HEK293 cells [42]. These attributes make BMEs attractive vehicle for targeted delivery 
of drugs and therapeutic nucleic acids to diseased tissues.  
The traditional approach of studying BMEs is fraught with huge variability and inefficient due to 
the challenging isolation and limited cargo loading procedure. The reason being that BMEs quality 
and their cargo profiles are significantly affected by several factors such as the physiological state 
of their parent cells, isolation techniques and sample processing [43]. The common isolation 
techniques such as ultracentrifugation, density gradient centrifugation, salting out and size 
exclusion allow enrichment of exosomes but with low purity as natural bovine milk contains stable 
multi-protein complexes that share comparable size with BMEs. Some free proteins even 
specifically complex with BMEs surface and co-precipitate during isolation procedure causing 
confounding effects on downstream analyses [44]. Also, the current loading of functional 
biomolecules into BMEs is passive and too inefficient for targeted drug delivery. Passive loading 
entails encapsulation of biomolecules into purified exosomes by electroporation, repeated freeze 
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thawing, sonication, or even extrusion of natural cargos for a more functional one [45]. During 
this loading process, the exosomes membrane is temporarily disrupted and incubated with 
functional biomolecule which diffuses into the interior through the pores created on the exosomes. 
The major limitations of this method are as follows: (1) it is non-targeted; (2) loading efficiency 
depends on diffusion through a concentration gradient and the interaction between biomolecules 
and the phospholipid membrane of the exosomes; (3) It may lead to distortion of exosomes 
integrity. [26, 46, 47] 
To accelerate BMEs studies for targeted therapeutic application, there is need to employ a more 
controlled in vitro cell system that will ensure reproducible isolation of pure BME preparations 
and allow functional biomolecules to be efficiently loaded into BMEs using gene technology [48]. 
Bovine mammary epithelial cell (MAC-T) is the functional unit of milk secretion and the primary 
origin of milk exosomes [49]. MAC-T cell is widely regarded as a reliable in vitro model for the 
studies of mammary gland functions because of its expression of milk-specific proteins [50] and 
thus is ideal for studying genetic modifications in BMEs.  
Many studies have explored the surface modification of exosomes for imaging and targeting 
purposes using genetic engineering. Genetic engineering of donor cells for exosomal cargo loading 
offers the following benefits: ability to load encodable targeting ligands, imaging agents, 
antibodies or other functional biomolecule into exosomes with high efficiency, precision and 
specificity; minimal interference with exosomes surface proteins; and the flexible packaging of 
biomolecules in the interior and/or exterior surface of exosomes [48]. To genetically modify 
exosomes, the transgene is first fused to exosome-specific markers such as CD81, CD9 and CD63 
etc. and then expressed in the donor cells by plasmid transfection. Transformed donor cells then 
secrete engineered exosomes with the functional protein attached to their surface [51]. For 
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example, previous studies have produced brain targeting dendritic cell-derived exosomes by 
expressing a fusion of the central nervous system specific rabies viral glycoprotein (RVG) peptide, 
and exosomes specific protein, Lamp2b, in murine dendritic cells. The transformed dendritic cells 
secreted RVG-exosomes that crossed the blood-brain barrier (BBB). When loaded with β-site 
amyloid precursor protein cleaving enzyme 1 (BACE1) siRNAs, these engineered exosomes 
delivered their cargos to brain cells where they induced a 62% reduction in BACE1 mRNA 
expression [52]. Another study expressed a fusion protein consisting of ischemic myocardium‐
targeting peptide (IMTP) and Lamp2b in bone marrow mesenchymal cells (BMSCs) and the 
transformed cells secreted engineered exosomes that showed increased uptake by ischemic 
myocardium compared to unmodified exosomes [53]. Aside from the packaging of targeting 
peptides, donor cells can be genetically modified to load highly sensitive fluorescent proteins into 
exosomes to visualize and monitor their biodistribution, viability, and biological 
activity/therapeutic efficiency in vivo [35, 54]. Traditionally, fluorescent lipophilic dyes are used 
to label BMEs, but this labelling approach is inefficient due to non-specificity, release of dyes 
from exosomes membranes, long half-life of chemical dyes and generation of non-exosomes 
related signals [55]. In contrast, gene labeling technology increases the stability and exosome-
specificity of fluorescent proteins thereby providing an accurate assessment of the spatiotemporal 
distribution of exosomes [56, 57]. Some studies have endogenously labeled exosomes by fusing 
fluorescent transgenes such as eGFP, RFP, iRFP, Zsgreen1, exosomes-enriched markers such as 
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Bovine milk exosomes (BMEs) have attracted attention as vehicles for delivering RNA 
therapeutics. BMEs originate in mammary alveolar cells. Here, we determined whether bovine 
mammary alveolar MAC-T cells are a promising tool to assess RNA delivery by BMEs. MAC-T 
cells exosomes (MAC-T BMEs) and BMEs were harvested by differential ultracentrifugation. 
Exosome size, morphology, microRNA content and marker proteins were assessed using 
nanoparticle tracking analysis, transmission electron microscopy, real-time PCR and immunoblot 
analysis, respectively. MAC-T cells were genetically engineered to secrete MAC-T BMEs 
endogenously labeled with a near-infrared fluorescent protein and tissue distribution was 
compared to fluorophore-labeled BMEs following intravenous injection in C57BL/6 mice. 
Morphology and size were similar in MAC-T BMEs and BMEs (94 ± 5.8 nm and 101 ± 4.2 nm, 
p > 0.05). Both preparations expressed miR-320a, miR-200c and let-7a-5p (positive controls) but 
not miR-1 (negative control). Exosome marker proteins, CD9, CD63, CD81 and Tsg101, were 
detected in both MAC-T BMEs and BMEs. The distribution in mouse tissues was similar for 
both preparations, with liver being the primary accumulation site. Collectively, MAC-T BMEs 
afford are a promising tool for BMEs-based RNA delivery studies.  
Key words: Bovine mammary alveolar MAC-T cells; bovine milk exosomes; CD81 fusion 





Nanoparticles are promising tools for delivering therapeutics, including the delivery of small 
interfering RNA (siRNA) to sites of disease such as tumors [1]. Nanotechnology offers a variety 
of advantages compared to the conventional method of delivering free drugs. For example, 
nanoparticles may facilitate the transfer of therapeutics across the blood-brain barrier and protect 
unstable RNA cargos against degradation [2, 3]. When self-derived exosomes from dendritic 
cells, modified by a brain homing peptide, rabies virus glycoprotein, were loaded with BACE1 
siRNA and delivered by intravenous injection, the expression of BACE1 mRNA and protein 
decreased by 60% in neurons, microglia, oligodendrocytes and their precursors [4]. The 
technology was subsequently applied in the knockdown of other gene targets in mice and allele-
specific knockdown of oncogenic KRASG12D in mouse models of pancreatic cancer [5-7]. While 
the production of cell culture-derived exosomes is a promising technology, their use in drug 
delivery poses challenges such as limited drug loading efficiency and lack of standardized 
isolation and purification methods [8]. 
Bovine milk exosomes (BMEs) have attracted attention for use in drug delivery because of the 
following observations. BMEs and their RNA cargos are bioavailable after oral administration 
and cross the blood-brain barrier (BBB) in humans, mice and pigs [9-11]. The cellular uptake of 
BMEs is facilitated by endocytosis in endothelial cells [12]. BMEs confer protection to RNA 
cargos against the harsh conditions encountered in the gastrointestinal tract (low pH, RNase) and 
in industrial processing of milk [13, 14]. BMEs may be loaded with small RNAs by using 
calcium chloride and ethanol [11]. BMEs do not elicit a significant immune reaction in humans 
in vivo and ex vivo, and in rats [15, 16], which is an important consideration when pursuing 
federal approval of a drug [17]. The production of BMEs is scalable. On average, a cow 
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produces 10,800 kg of milk annually in the U.S. in 2020, and milk contains approximately 1012 
exosomes per milliliter [13, 18].  
Here, we sought to establish a tool that accelerates the rate of discovery in drug delivery by 
BMEs by comparing morphology, size and content and tissue distribution in BMEs and 
exosomes secreted by bovine mammary alveolar MAC-T cells [19], and by assessing whether 
MAC-T cells and their exosomes are amenable to genetic engineering. MAC-T cells were chosen 
as cell model because evidence suggests that BMEs originate in bovine mammary alveolar cells 
[20, 21].  
Materials and Methods 
Cell Cultures 
Bovine mammary alveolar MAC-T cells were derived from primary bovine mammary alveolar 
cells and immortalized using SV-40 large T antigen [19]. The MAC-T cells were a kind gift by 
Dr. Thomas McDonald at the University of Nebraska Medical Center. MAC-T cells were 
cultured as previously described [19]. Briefly, MAC-T cells were plated in T175 flasks (cat. # 
12-556-011, Thermo Scientific) at a density of 2.5 x 106 in Dulbecco’s modified eagle medium 
(DMEM) (cat. # SH30284.02, Cytiva) supplemented with 10% fetal bovine serum (cat. # S1150-
Nov, Novus Biologicals), 5 µg/ml Insulin (cat. # 91077C-100MG, Sigma-Aldrich), 1 µg/ml 
hydrocortisone (cat. # H0396, Sigma-Aldrich) and 1% penicillin-streptomycin mixture (cat. # 
17-602E, Lonza). The fetal bovine serum was conditioned by depleting exosomes through 
centrifugation at 120,000 g for 18 hours. 
Exosome Isolation and Authentication 
Exosomes were isolated from of MAC-T cell culture-conditioned media (containing exosome-
depleted fetal bovine serum) and store bought bovine milk by differential ultracentrifugation 
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using a F37L-8×100 rotor as previously described [10]. Hereafter, we refer to MAC-T cell 
derived exosomes as MAC-T BMEs. Protocol details are available through the EV-Track 
database (ID: EV210158). Purified exosome pellets were resuspended in 500 µl of phosphate 
buffered saline and stored at -80oC until analysis unless stated otherwise. 
MAC-T BMEs and BMEs were thawed at room temperature and diluted as required for 
assessment of size and count by using a NanoSight NS300 tracking instrument (Malvern, 
Westborough, MA). We used the following instrument settings: camera level 14, detection 
threshold 5, syringe speed 100 and five 1-minute videos (technical replicates) per biological 
replicate (n = 3). Data were analyzed by using NTA 2.3 software (Malvern). 
Morphology and dispersion of exosomes were assessed by using transmission electron 
microscopy [22]. Briefly, the exosomes were fixed, stained with phosphotungstic acid (3 mM), 
and analyzed as previously described using a Hitachi H7500 microscope in the Nebraska 
Microscopy Core at the University of Nebraska-Lincoln. 
Exosomes were further authenticated by immunoblot analysis using positive and negative marker 
proteins as follows [23]. Protein extraction and analysis were performed as previously described 
by [10]. Protein concentrations were assayed by using the bicinchoninic acid assay (cat. # HY-
K1001, MedChem Express) and 50 µg total protein from exosomes and cell lysates were 
separated on 4-12% Bis-Tris Protein Gels (cat. # NP0322, Thermo fisher). Transblots on PVDF 
membranes were probed with the following antibodies: mouse anti-bovine CD9 (cat. # 
GTX76185, Genetex), mouse anti-bovine CD63 (cat. # MCA2042GA, BioRad), rabbit anti-
human CD81 (cat. # ab 155760, Santa Cruz) and rabbit anti-bovine TSG101 (cat. # sc-7964, 
Santa Cruz) as exosome markers; and rabbit anti-mouse calnexin (cat. # ab7580, Abcam,) as a 
negative control. Protein bands were visualized by using IRDye 800CW-conjugated goat anti-
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mouse (cat. # 926-32210, LI-COR Biosciences) or IRDye 800CW-goat anti-rabbit (cat. # 926-
32211, LI-COR Biosciences) and an Odyssey Clx Imaging System (LI-COR, Inc. Biosciences). 
MicroRNA Analysis  
Quantitative real time PCR (qPCR) was used to assess the presence of microRNAs in MAC-T 
cell exosomes as previously described [24]. Cel-miR-39 was added to the samples during the 
isolation process as a spike-in control for the efficiency of RNA extraction and cDNA synthesis 
[9]. The expression levels of three milk enriched microRNAs, miR-320a, miR-200c and let-7a-
5p were assessed by qPCR using the universal reverse primer in the miScript SYBR Green PCR 
kit (cat. # 218073, Qiagen) and microRNA-specific forward primers (Table S. 1). MiR-1 is not 
present in BMEs and was used as negative control [9]. Cycle threshold (Ct) values greater than 
29 were considered not detectable (N.D.) [25]. 
Genetically Engineered MAC-T Cells 
MAC-T cells were genetically engineered to secrete transgenic exosomes containing a fusion 
protein composed of the tetraspanin CD81, near-infrared fluorescent protein (iRFP) and a 
polyhistidine tag (Supplementary Fig. 1). CD81 is a well-established exosome marker [26]. The 
feasibility of labeling CD81 through a fusion of a fluorescent protein to the C-terminus was 
previously demonstrated  [27]. The design of the plasmid positions iRFP and polyhistidine inside 
exosomes, which minimizes the impact on the outer exosome surface and therefore tissue 
distribution [28]. iRFP has physicochemical properties conducive to successful tracking of 
exosomes in animals, e.g., minimal photodamage, low auto-fluorescence and deep tissue 
penetration [29, 30]. To construct the plasmid, individual fragments of bovine CD81 (726 bp) 
and iRFP (978 bp) were amplified from MAC-T cell cDNA and piRFP plasmid (cat. # 31857, 
Addgene), respectively, using Q5 High-Fidelity DNA Polymerase kit (cat. # M0491S, New 
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England Biolabs) and the PCR primers shown in Supplementary Table 2. The open reading 
frame encoding the CD81-iRFP-polyhistidine fusion protein (1704 bp) was obtained by joining 
the PCR products using overlap PCR [31] with the primers denoted CD81_forward and 
iRFP_His reverse in Supplementary Table 2. The following program was used for overlap PCR: 
initial denaturation at 98°C for 2 minutes followed by 17 cycles of 98°C for 15 seconds 
(denaturing), 67°C (−0.5°C/cycle) for 15 seconds (annealing) and 72 °C for 30 seconds 
(extension). The first round of PCR was followed by another 23 cycles: 98°C for 15 seconds 
(denaturing), 59°C for 15 seconds (annealing), 72°C for 45 seconds (extension) and a final 
denaturation step at 72°C for 2 minutes. The product was cloned into a pCDH-puro lentiviral 
plasmid (cat. # 46970, Addgene, Watertown, MA). Absence of mutations was confirmed by 
sequencing analysis and the plasmid is hereafter referred to as pCDH-CD81-iRFP 
(Supplementary Fig. 1). 
The pCDH-CD81-iRFP plasmid, envelope plasmid (pMD2.G, cat. # 12259, Addgene) and 
packaging plasmid (psPAX2, cat. # 1226, Addgene) were co-infected into HEK-293T cells using 
attractene (cat. # 301005, Qiagen), following the manufacturer’s protocol, and lentiviral particles 
were collected by precipitation using standard PEG 8000 as previously described (Au - Baumlin-
Schmid et al. 2016). MAC-T cells were transfected with lentiviral particles using polybrene (cat 
# 107689-10G, Sigma Aldrich) and stably transformed cells were selected using puromycin (2 
µg/ml). MAC-T BMEs were collected by differential ultracentrifugation from 72-hour cultures 
of MAC-T cells and the expression of iRFP in MAC-T BMEs and cells was assessed by using an 
Odyssey Clx Imaging system (LI-COR Biosciences, Inc.). 
Tissue Distribution of MAC-T BMEs in Mice 
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We compared the tissue distribution of iRFP-labeled MAC-T BMEs and HiLyte-labeled BMEs 
in C57BL/6 mice at 6 weeks of age (Jackson laboratory, stock number 000664) were assessed 
and compared. BMEs were labeled with carbonyl-reactive HiLyte 750 (cat. # 61183, AnaSpec 
Inc., San Jose, CA) following the manufacturer’s recommendations. We chose a dose of 1 x 1011 
exosomes/g body weight for tail vein injection of iRFP-labeled MAC-T cell BMEs, HiLyte 750-
labeled BMEs and controls (unlabeled MAC-T BMEs and unlabeled BMEs) based on the 
rationale that the dose produced a robust signal in a previous study [11]. The mice were 
euthanized 3 hours after injection when tissues were excised and washed with cold phosphate 
buffered saline. iRFP and HiLyte 750 fluorescence was analyzed using the 700-nm and 800-nm 
filters, respectively, in an Odyssey Clx Imaging System. The fluorescence signal was corrected 
by the signal from unlabeled controls. Densitometry analyses were performed by using LI-COR 
Image studio 5.2 software. The percent tissue distribution was calculated by dividing the 
fluorescence signal in individual tissues by the fluorescence signal from all tissues combined and 
multiplying that value by 100. All animal procedures were conducted in accordance with the 
University of Nebraska-Lincoln’s Institutional Animal Care and Use Committee and approved 
by the Institutional Animal Care Program (protocol 1713). 
Statistical Analyses 
Homogeneity of variances was assessed using Levene’s test. Normality of distribution was 
confirmed by using the Shapiro-Wilk test. Data analysis was performed using unpaired student’s 
t test. All statistical analyses were performed using Prism 6 (Graph pad software Inc.). Data are 
expressed as means ± SEM as denoted in tables and figures. Differences were considered 




Characterization of MAC-T BMEs 
The morphology and size were similar in MAC-T BMEs and BMEs from milk. Both 
preparations presented as spherical membranous structures in TEM (Fig. 1). Nanoparticle 
tracking analysis revealed a homogenous particle distribution with a similar mean size of 94 ± 
5.8 nm and 101 ± 4.2 nm for MAC-T exosomes and BMEs, respectively (Fig. 2). Both 
preparations expressed the exosome marker proteins CD9, CD63, CD81 and Tsg101 at the 
expected sizes, whereas a marker of microvesicles, calnexin, was detectable only in MAC-T cell 
lysate (Fig. 3).  
MicroRNA Content 
MAC-T BMEs and BMEs from milk expressed the three microRNAs we analyzed (positive 
controls, whereas miR-1 (negative control) was not detectable (Ct > 29 cycles) in any of the 
samples (Table 1). The expression of let-7a-5p and miR-200c was lower in MAC-T BMEs than 
in BMEs.  
Expression of CD81-iRFP-His in MAC-T cells and MAC-T BMEs 
MAC-T cells were transformed to express a CD81-iRFP-polyhistidine fusion protein, which 
localized to exosomes. Successful transformation and localization to exosomes was 
demonstrated as follows. Transformed MAC-T cell expressed iRFP, evidenced by the emission 
of near-infrared fluorescence (Fig. 4a). The image was taken after 8 passages of MAC-T cells, 
consistent with stable transformation. Media from cultures of transformed MAC-T cells 
produced strong near-infrared fluorescence suggesting secretion of the fusion protein by cells 
into the extracellular space (Fig. 4b); media from non-transformed MAC-T cells produced no 
fluorescence (control). iRFP fluorescence remained detectable in the supernatant from 16,000 g 
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and 83,000 g centrifugation steps, but localized to the pellet following centrifugation at 130,000 
g (Fig. 4c, depicting the pellet suspended in PBS). The vesicles in the 130,000 g pellet had a 
mean size of 82 ± 1.2 nm (Fig. 5a) which is similar to exosomes secreted by non-transformed 
MAC-T cells (Fig. 2). The vesicles in the 130,000 g pellet tested positive for exosome markers, 
CD81 and Tsg101 (Fig. 5b). The position of the CD81 band was as expected for a CD81-iRFP-
polyhistidine fusion protein, suggesting absence of degradation. The combination of 
centrifugation and size data, as well as protein markers suggests that the CD81-iRFP-
polyhistidine fusion protein localized to exosomes.  
Tissue Distribution of Transformed MAC-T BMEs in C57BL/6 Mice 
The tissue distribution was similar for CD81-iRFP-positive MAC-T BMEs and HiLyte-labeled 
BMEs from milk following their intravenous injection in C57BL/6 mice. Both preparations 
accumulated primarily in the liver, but some accumulation was also apparent in the intestinal 
tract, lungs, kidneys, and spleen in both male and female mice (Fig. 6). The distribution of the 
two preparations differed in a few tissues. For example, the percent accumulation in brain and 
intestinal tract was higher for iRFP-labeled MAC-T BMEs than for HiLyte-labeled BMEs in 
both male and female mice. HiLyte-labeled BMEs produced a stronger fluorescence signal in 
murine tissues than iRFP MAC-T BMEs in both male and female mice (Supplementary Fig. 2). 
Discussion 
This is the first report introducing a bovine cell model amenable to genetic engineering for 
studies of BMEs in drug delivery. While the use of BMEs for delivering drugs has attracted 
considerable attention, previous modifications of BMEs were limited to the use of labeling and 
loading strategies [11, 16, 32-34]. MAC-T cells a promising tool for accelerating the rate of 
discovery in the field of BMEs and their use in nanotherapy.  
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This study provides compelling evidence that morphology, size, and microRNA cargos are 
similar in MAC-T BMEs and BMEs, and exosomes from both sources have comparable tissue 
distribution profiles when administered intravenously to mice. MAC-T BMEs were authenticated 
by following recommendations by the International Society for Extracellular Vesicles (ISEV) 
[35]. Extensive authentication as well as the use of endogenous labeling approaches and the 
disclosure of protocol details in the EV-Track database enhance the rigor, reproducibility and 
transparency of this study.  
CD81 is an exosome marker protein [26, 36]. Its choice for iRFP fusions, in addition to 
precipitation in the 130,000 g fraction during ultracentrifugation, absence of precipitation at low 
speed, morphology, size and marker proteins suggests that the CD81-iRFP localized to 
exosomes. The demonstration that MAC-T cells are amenable to genetic engineering makes 
them a potentially powerful tool in studies of nanotherapy. 
This study adds to the existing body of evidence that milk exosomes originate in the mammary 
gland, which was previously supported by circumstantial evidence that epithelial cells are 
abundant in human milk and microRNA profiles are similar in BMEs in the lactating mammary 
gland in cows [20, 21]. We acknowledge that this study does not provide an unambiguous 
answer to the question where BMEs originate, but that was not this study’s goal. 
This study and the use of MAC-T cells has the following limitations. The amount of BMEs 
harvested from MAC-T cell cultures is small when done in a research laboratory setting. For 
example, we harvested approximately 1011 MAC-T BMEs from 350 mL of culture media in 3-
day cultures. That said, we achieved our primary goals of characterizing exosomes from 
transformed and non-transformed MAC-T cells and assessing the tissue distribution in mice, 
which informs future large-scale studies. Note that the accumulation of MAC-T BMEs in the 
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murine brain was considerably less than the accumulation of (allogeneic) murine milk exosomes 
in the murine brain in our previous studies [11]. We propose that interactions between species-
specific proteins on the exosome surface and the surface of receptor cells contributed to the 
observed difference. The role of protein-protein interactions in facilitating cellular exosome 
uptake has been reviewed [37]. Consistent with this theory, Wiklander et al. have enhanced the 
accumulation of exosomes in the brain through the expression of a brain homing signal, rabies 
virus glycoprotein [38]. Additional factors that might have contributed to the differences in brain 
accumulation include the route and timing of exosome administration, i.e., acute intravenous 
injection in this study compared to chronic oral intake in our previous study [11]. 
We conclude that MAC-T cells and BMEs are promising tools for optimizing drug delivery by 
milk exosomes. Future studies include the assessment of oral bioavailability and immunogenic 
potential of MAC-T BMEs. 
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MAC-T BMEs      BMEs 
Figure 2. 1 Transmission electron microscopy images of MAC-T BMEs and BMEs. Large field: 










Figure 2. 2 Nanoparticle tracking analysis of MAC-T BMEs and BMEs. Values are expressed as 
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Figure 2. 3 Immunoblot analysis of protein extracts from BMEs, MAC-T BMEs, and MAC-T 



































































Figure 2. 4 Expression of a CD81-iRFP fusion protein in genetically engineered MAC-T cells 
and their exosomes. (a) Expression of CD81-iRFP in non-transformed (NT) and transformed 
MAC-T cells after 8 passages. (b) CD81-iRFP in media from non-transformed and transformed 









       
Figure 2. 5 Authentication of engineered MAC-T BMEs. (A) Nanoparticle tracking analysis of 
non-transformed (NT) MAC-T cells and transformed MAC-T cells. Values are shown as mean ± 
SEM. p > 0.05 (n= 3). (B) Immunoblot analysis of CD81 and Tsg101 in exosomes from non-
transformed (NT) MAC-T cells and transformed MAC-T cells. 
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Figure 2. 6 Tissue distribution of iRFP-labeled MAC-T BMEs and HiLyte-labeled BMEs in 
male (left) and female (right) C57BL/6 mice. The percent tissue distribution was assessed 3 
hours after intravenous injection of 1.0 x 1011 exosomes/g body weight. Values are expressed as 
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Figure S 1. Schematics illustration of CD81-iRFP vector construction. (A) Configuration of 





Figure S 2. Biodistribution of MAC-T BMEs and HiLyte BMEs in mice tissues. Fluorescence in 
excised tissues of C57BL/6 mice of after intravenous injection of iRFP MAC-T BMEs, 









*Value = Ct (cycle threshold); mean ± SEM; n=3; ap ≤ 0.05 vs BMEs. 
ND, not detectable. 
  
Samples let-7a miR-200c miR-320a miR- 1 
MAC-T BMEs 28.1 ± 0.7
a
 26.3 ± 0.4
a
 25.4 ± 0.8  ND 
BMEs 23.5 ± 1.8
a
 21.4 ± 1.2
a
 24.2 ± 1.2  ND 
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1Qiagen’s miScript Universal Primer was used as reverse primer for all reactions. miSpike is a 






MicroRNA  Forward Primer (5’-3')1  
miR-320a  AAAAGCTGGGTTGAGAGGGCGA  
miR-200c  TAATACTGCCGGGTAATGATGGA     
let-7a-5p  TGAGGTAGTAGGTTGTATAGTT      
miR-1 TGGAATGTAAAGAAGTATGTAT 
miSpike  CTCAGGATGGCGGAGCGGTCT  
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 Primer/ Template Sequence (5’-3’) Product 
size (bp) 
 CD81_reverse GCCGCCCGAGCCGCCGCCTGAGGAGCCGCCGTACACCGAGCTGTT  726 
 iRFP-His_ forward GGCGGCTCCTCAGGCGGCGGCTCGGGCGGCGCTGAGGGAAGCGTG  978 
 CD81-iRFP-His_forward GATGAATTCATGGGGGTAGAGGGCTGCACCAAG  




BMEs have attracted attention as drug delivery vehicles because they are safe, scalable, and 
bioavailable. The drug delivery potentials of BMEs are still yet to be harnessed due to limited 
cargo loading and drug delivery modalities. Hence, an urgent need to explore a lab-friendly cell 
model that will facilitate the genetic reprogramming of BMEs for improved drug delivery. We 
addressed this lacuna by demonstrating that MAC-T cells secrete exosomes that are like BMEs, 
and these cells are amenable to genetic modifications for drug delivery studies. While our 
findings are a major milestone in the BMEs research community, MAC-T BMEs still merit 
further exploration. 
Although we showed that MAC-T BMEs exhibit similar tissue distribution patterns with BMEs, 
we have not assessed their immunogenic effects in vivo. Induction of immune response is an 
important phenomenon that must be avoided in drug delivery studies as this might lead to 
confounding health consequences in clinical settings. Hence, this remains a fruitful line of 
investigation. 
Additionally, our lab has shown that orally administered BMEs and their miRNA cargos are 
stable under harsh gastric conditions and penetrate the intestinal mucosa where they are absorbed 
into systemic circulation. Future studies should explore the therapeutic efficacy of MAC-T 
BMEs enclosed miRNA and siRNA therapeutics in the treatment of colorectal cancer and the 
possibilities of moving them into clinical trials considering their safety and bioavailability 
following oral intake.  
This study sets the bar for the improvement of BMEs for targeted drug delivery through protein 
engineering in MAC-T cells. Given the amenability of MAC-T BMEs to genetic engineering, 
subsequent studies should focus on the development of trackable engineered BMEs capable of 
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targeting different tissues with precision. We observed that autologous milk exosomes have 
higher brain accumulation compared to exogenous exosomes. Further studies need to investigate 
the surface protein(s) that are involved in their increased uptake and how it can be incorporated 
into MAC-T BMEs for improved drug delivery to the brain. Currently, our lab is actively 
conducting studies on genetically modified MAC-T BMEs for improved tumor targeting, 
increased systemic stability, and reduced intracellular degradation. Findings from this study will 
















Table 3. MiRNA analysis data for MAC-T BMEs and BMEs 
 
   
 
 
Samples Replicate 1 Replicate 2 Replicate 3 Mean SEM 
MAC-T BMEs 87.3 105.3 88.2 94 5.8 
BMEs 97.7 108.9 95.3 101 4.2 
Samples Replicate 1 Replicate 2 Replicate 3 Mean SEM 
IRFP MAC-T 
BMEs 
80.4 84.6 82.2 82  
 
1.2  
MAC-T BMEs 87.3 105.3 88.2 94 5.8 
 Let 7a  Mean SEM 
MAC-T 
BMEs 
29.25 29.70 29.51 
29.49 
  
 27.37 27.83 27.43 27.54 28.13 0.68 
 27.50 27.44 27.10 27.35   
BMEs 22.86 23.00 23.05 22.97   
 20.83 20.49 20.81 20.71 23.54 1.80 
 27.05 27.01 26.76 26.94   
 miR200c  Mean SEM 
MAC-T 
BMEs 
27.30 27.07 27.02 27.13 
  
 25.92 25.76 25.48 25.72 26.32 0.40 
 26.10 26.11 26.12 26.11   
BMEs 21.17 21.52 21.31 21.33   
 19.20 19.19 19.24 19.21 21.35 1.23 
 23.52 23.37 23.60 23.50   
MAC-T 
BMEs 
miR320a  Mean SEM 
 24.71 24.42 23.97 24.37   
 24.88 24.60 25.06 24.85 25.39 0.79 
 26.96 27.05 26.87 26.96   
BMEs 23.94 24.04 24.02 24.00   
 22.23 22.29 22.36 22.29 24.22 1.18 




Table 4. Percent tissue distribution data in male and female mice. 
 
 
Female Percent Tissue distribution 
 iRFP MAC-T BMEs HiLyte BMEs 
 Replicates   Mean  SEM Replicates Mean SEM 
Brain 5.04 9.24 9.61 7.96 1.47 0.09 0.12 0.12 0.11 0.01 
Heart 0.73 1.13 1.76 1.21 0.30 2.88 3.88 1.90 2.89 0.57 
Lungs 7.16 4.39 5.82 5.79 0.80 36.37 17.61 37.68 30.55 6.48 
Kidneys 3.39 8.16 4.31 5.29 1.46 5.20 8.19 8.38 7.26 1.03 
Spleen 2.09 6.41 6.26 4.92 1.42 6.68 12.04 9.27 9.33 1.55 
Intestinal 
tract 
30.70 33.95 25.78 30.14 2.37 9.40 9.71 7.33 
8.81 0.75 
Liver 50.90 36.71 46.45 44.69 4.19 39.37 48.45 35.32 41.05 3.88 
           
Male Percent Tissue Distribution 
 iRFP MAC-T BMEs HiLyte BMEs 
 Replicates Mean SEM Replicates Mean SEM 
Brain 2.96 1.71 5.58 3.42 1.14 0.35 0.33 0.70 0.46 0.12 
Heart 0.95 1.01 1.35 1.10 0.12 1.63 1.03 1.03 1.23 0.20 
Lungs 7.13 6.91 10.42 8.15 1.14 38.28 47.04 3.57 29.63 13.27 
Kidneys 4.98 7.10 6.32 6.13 0.62 4.07 4.47 8.68 5.74 1.47 
Spleen 0.86 4.29 2.28 2.48 1.00 7.34 7.86 13.80 9.67 2.07 
Intestinal 
tract 
10.57 13.50 10.53 11.53 0.98 2.37 4.33 2.85 3.18 0.59 
Liver 72.54 65.48 63.51 67.18 2.74 45.95 34.94 69.38 50.09 10.16 
